Top 7 China Herbal Medicine Companies 2025
China's traditional herbal medicine (TCM) industry is valued at over ¥1 trillion annually, combining thousands of years of herbal therapy tradition with modern pharmaceutical science. The industry encompasses herbal medicine manufacturing, herbal cultivation, TCM hospital services, and herbal wellness products. China produces over 10,000 types of herbal medicines and botanical drugs from approximately 12,000 medicinal plant species. Key growth drivers include government policy support for TCM development, aging population demand, international expansion, and the integration of AI and modern science into traditional herbal formulations.
Tong Ren Tang (同仁堂)
Revenue: ¥20B+ (2024)
Tong Ren Tang, founded in 1669, is China's most prestigious traditional Chinese medicine brand with over 350 years of continuous operation. Designated as a supplier to the Qing Dynasty imperial court, the company maintains strict quality standards for its herbal medicines, pills, and health products. Tong Ren Tang operates pharmacies, hospitals, and manufacturing facilities across China and internationally. The company's signature products include Angong Niuhuang Wan (brain health pill), Liuwei Dihuang Wan (kidney tonic), and various herbal teas and wellness products.
Yunnan Baiyao (云南白药)
Revenue: ¥35B+ (2024)
Yunnan Baiyao is one of China's best-known herbal medicine companies, famous for its namesake Yunnan Baiyao powder — a proprietary herbal formula used for wound healing, bleeding control, and pain relief for over 100 years. The company has expanded beyond its signature powder into toothpaste (China's #1 herbal toothpaste brand), herbal patches, sprays, and skincare products. Yunnan Baiyao holds state-level secret formula protection status, meaning its core ingredient composition remains confidential.
Yiling Pharmaceutical (以岭药业)
Revenue: ¥10B+ (2024)
Yiling Pharmaceutical is a leading modern TCM company known for developing herbal medicines through rigorous clinical trials and scientific research. The company's flagship product, Lianhua Qingwen (连花清瘟), became one of China's most widely used herbal medicines during COVID-19 for respiratory symptoms. Founded by academician Wu Liandui, Yiling specializes in cardiovascular and cerebrovascular herbal medicines including Qili Qiangxin and Tongxinluo capsules.
TASLY Pharmaceutical (天士力)
Revenue: ¥8B+ (2024)
TASLY is a leading Chinese pharmaceutical company specializing in modernized TCM products with international reach. The company's flagship product, Compound Danshen Dripping Pill (复方丹参滴丸), was the first Chinese herbal medicine to complete FDA Phase II clinical trials in the United States. TASLY has invested heavily in modernizing herbal medicine production with pharmaceutical-grade GMP facilities and pursuing international regulatory approvals for its herbal products across 30+ countries.
Buchang Pharma (步长制药)
Revenue: ¥15B+ (2024)
Buchang Pharma is China's largest TCM company focused on cardiovascular and cerebrovascular diseases. The company's signature product, Naoxintong (脑心通), is one of China's best-selling herbal medicines for stroke prevention and treatment. Buchang operates a comprehensive TCM value chain from herb cultivation to finished product manufacturing, with GMP-certified facilities and an extensive sales network across 30,000+ hospitals and pharmacies in China.
Kangmei Pharmaceutical (康美药业)
Revenue: ¥5B+ (2024)
Kangmei Pharmaceutical is a major Chinese herbal medicine company operating across herbal cultivation, processing, manufacturing, and distribution. The company manages one of China's largest herbal medicine trading markets and operates nationwide pharmacy chains. Despite financial difficulties in 2019-2022, Kangmei has restructured and continues to be a significant player in China's herbal medicine supply chain, operating herbal medicine markets in Pu'er (Yunnan) and other major trading centers.
Guangzhou Pharmaceutical (广药集团)
Revenue: ¥25B+ (2024)
Guangzhou Pharmaceutical (GPHL) is one of China's largest pharmaceutical groups, with a strong TCM division encompassing traditional herbal medicines, herbal teas, and health products. The group's brands include Wanglaoji (王老吉) herbal tea — China's most popular herbal beverage with ¥30B+ annual revenue — along with multiple herbal medicine brands like Chen Li Ji (陈李济, founded 1600) and Panbai Pharmaceutical. GPHL operates one of China's largest herbal medicine manufacturing and distribution networks.
Comparison Table
| Company | Specialty | Revenue | Heritage | Global Reach | R&D | Growth |
|---|---|---|---|---|---|---|
| Tong Ren Tang | Premium herbal | ¥20B+ | 350+ years | Global retail | Traditional | Moderate |
| Yunnan Baiyao | Wound healing | ¥35B+ | 100+ years | Growing export | Modern | 15%+ |
| Yiling Pharma | Modern TCM | ¥10B+ | 30 years | Clinical trials | Leading | 20%+ |
| TASLY | Modernized TCM | ¥8B+ | 30 years | FDA trials | Advanced | 15%+ |
| Buchang Pharma | Cardiovascular | ¥15B+ | 25 years | Limited | Clinical | Moderate |
| Kangmei Pharma | Herbal supply | ¥5B+ | 25 years | Limited | Rebuilding | Recovery |
| Guangzhou Pharma | Herbal beverage | ¥25B+ | 400+ years | Global (tea) | Moderate | 10%+ |
Frequently Asked Questions
How large is China's traditional herbal medicine industry?
China's traditional Chinese medicine (TCM) industry exceeds ¥1 trillion in annual revenue, encompassing herbal medicine manufacturing (¥500B+), TCM hospital services (¥300B+), herbal health products (¥150B+), and herbal cultivation (¥50B+). China has over 6,000 TCM hospitals and 50,000+ TCM clinics. The TCM industry employs approximately 10 million people across the value chain from herb cultivation to manufacturing and healthcare services. The industry has been growing at 8-12% annually, driven by government policy support and aging population demand.
What is China's most famous herbal medicine?
China's most famous herbal medicines include: Yunnan Baiyao — proprietary wound healing powder with state secret formula status, used for over 100 years; Tong Ren Tang's Angong Niuhuang Wan — premium brain and consciousness herbal pill from imperial court tradition; Lianhua Qingwen — modern antiviral herbal formula that became widely used during COVID-19; Compound Danshen Dripping Pill — TASLY's cardiovascular herbal medicine undergoing FDA trials; and Wanglaoji herbal tea — consumed as both beverage and traditional cooling remedy for over 180 years.
How does China regulate herbal medicine?
China's herbal medicine is regulated by the National Medical Products Administration (NMPA) through a dual system: (1) Classical TCM formulas — traditional formulations documented in historical pharmacopeia receive accelerated approval based on historical use evidence; (2) Modern TCM drugs — new herbal formulations must undergo full clinical trials similar to Western pharmaceuticals. The Chinese Pharmacopoeia lists approximately 6,000 herbal medicine entries. China also classifies certain premium herbal medicines as 'state-level protected varieties' with 30-year formula protection periods. Quality control standards require GMP certification for all herbal medicine manufacturers.
Can Chinese herbal medicine be exported internationally?
Chinese herbal medicine is exported to 190+ countries, though regulatory barriers vary significantly by market: (1) Dietary supplements — herbal products exported as food supplements face minimal regulatory requirements in most countries; (2) Pharmaceutical-grade TCM — requires FDA/EMA clinical trial data, only TASLY's Danshen Dripping Pill has completed FDA Phase II; (3) Traditional medicine registration — countries like Australia (TGA), Singapore (HSA), and several ASEAN nations have traditional medicine registration pathways. China's TCM export value exceeds $5 billion annually, with growing demand from the global wellness market. Key challenges include quality standardization, heavy metal contamination, and international clinical evidence requirements.
What is the future outlook for China's herbal medicine industry?
China's herbal medicine industry is projected to grow at 10-15% annually, reaching ¥2 trillion by 2030. Key growth drivers include: (1) Government policy support — the State Council's TCM Development Strategy 2030 plan prioritizes TCM integration into the healthcare system; (2) Aging population — China's 300M+ elderly population drives demand for chronic disease management through TCM; (3) International expansion — WHO inclusion of TCM in ICD-11 creates global regulatory pathways; (4) Digital transformation — AI-assisted TCM diagnosis, telemedicine herbal consultations, and e-commerce herbal product sales; (5) Preventive healthcare trend — growing consumer interest in wellness and preventive herbal products.